심혈관 의료기기 시장 예측(-2034년) - 디바이스 유형, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Cardiovascular Devices Market is accounted for $87.0 billion in 2026 and is expected to reach $185.3 billion by 2034 growing at a CAGR of 9.9% during the forecast period. Cardiology devices are medical equipment intended to diagnose, treat, and monitor diseases and cardiovascular systems. They play a vital role in healthcare by treating a range of cardiovascular disorders, including arrhythmias, coronary artery disease, and heart failure. Some of these devices are pacemakers, defibrillators, imaging equipment, monitoring systems, and catheters. Their importance derives from their capacity to provide effective treatment initiatives, facilitate precise diagnosis, and improve patient outcomes-all of which significantly raise standards for cardiac health and save lives.

According to the World Health Organization, around 75% of the cardiovascular diseases related deaths occur in low and middle income countries.

Market Dynamics:

Driver:

Rising prevalence of cardiovascular diseases

The rising prevalence of cardiovascular diseases (CVDs) such heart failure, arrhythmias, and coronary artery disease (CADD) is attributed to several factors, including sedentary lifestyles, unhealthy diets, tobacco use, and ageing populations. This escalating disease burden necessitates a greater demand for innovative cardiovascular devices and technologies. Devices such as implantable cardioverter-defibrillators (ICDs), pacemakers, drug-eluting stents, and cardiac monitoring devices play pivotal roles in diagnosing, treating, and managing various cardiovascular conditions. These advanced technologies aid in improving patient outcomes, reducing mortality rates, and enhancing the overall quality of life for affected individuals. Therefore, there is an increasing demand for market expansion.

Restraint:

Increasing barriers in R&D activities

Heightened regulatory scrutiny, demanding safety standards, and the necessity for extensive clinical trials significantly elevate R&D costs and timelines. These barriers disproportionately affect smaller companies and start-ups, limiting their ability to enter the market and innovate. Established players also encounter impediments, requiring substantial investments in R&D. These mounting hurdles in R&D hinder the timely introduction of novel cardiovascular devices, impeding innovation and market growth.

Opportunity:

Telemedicine and remote monitoring

Telemedicine and remote monitoring facilitate continuous patient care by enabling remote monitoring of vital signs, cardiac rhythms, and other relevant data in real-time. For cardiovascular patients, this offers the convenience of home-based monitoring, reducing hospital visits, and enhancing accessibility to healthcare. Advanced wearable devices, mobile apps, and connected platforms allow healthcare professionals to remotely assess patients' conditions, provide timely interventions, and offer personalised care, ultimately improving patient outcomes. The integration of telemedicine and remote monitoring in cardiovascular also opens avenues for innovation, driving the development of more sophisticated, user-friendly, and effective cardiovascular devices tailored for remote monitoring and telehealth applications.

Threat:

Stringent regulations

Evolving and stringent regulatory requirements can result in prolonged approval processes, increased compliance costs, and heightened barriers for new device introductions. These regulations may inhibit innovation and market entry, particularly for smaller companies with limited resources to navigate complex regulatory landscapes. Also, regulatory changes or uncertainties might disrupt existing market strategies and investments, impacting product development timelines and market competitiveness.

Covid-19 Impact

The COVID-19 pandemic significantly affected the cardiovascular device market in various ways. Initially, the focus shifted towards managing the pandemic, causing a decline in elective procedures and diagnostics for cardiovascular conditions due to healthcare resource reallocation and patient reluctance to seek non-emergency care. Supply chain disruptions and manufacturing constraints also impacted device availability. However, the pandemic accelerated the adoption of telemedicine and remote monitoring solutions, driving innovation in digital health for cardiovascular care. As vaccination rates increased and healthcare systems adapted to the new normal, there was a gradual rebound in elective procedures.

The Diagnostic and Monitoring Devices segment is expected to be the largest during the forecast period

The Diagnostic and Monitoring Devices segment is estimated to hold the largest share, due to the advanced technologies designed to detect, monitor, and assess cardiovascular conditions. They enable real-time monitoring of heart rhythms, blood pressure, and other vital signs, aiding in the early detection of abnormalities and facilitating continuous patient care. Additionally, these devices play a pivotal role in diagnosing various cardiovascular diseases, providing healthcare professionals with crucial data for accurate assessments, personalised treatment strategies, and improved patient outcomes, ultimately contributing to better management and care of cardiac

The Coronary Artery Disease (CAD) segment is expected to have the highest CAGR during the forecast period

The Coronary Artery Disease (CAD) segment is anticipated to have lucrative growth during the forecast period. Coronary artery disease (CAD) is a narrowing or blockage of your coronary arteries, which supply oxygen-rich blood to the heart. These devices help restore blood flow to the heart, alleviate symptoms, and reduce the risk of heart attacks. CAD-specific devices aid in interventions such as percutaneous coronary interventions (PCI) and coronary artery bypass grafting (CABG), playing a pivotal role in managing this prevalent cardiovascular condition and improving patients' cardiac health and quality of life.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. It encompasses a diverse landscape of medical technologies focused on treating heart-related conditions across countries like China, India, Japan, and others. This rapidly growing market features advancements in cardiac rhythm management devices, stents, diagnostic tools, and more. Moreover, factors such as rising cardiovascular diseases, improving healthcare infrastructure, and increasing adoption of innovative medical solutions contribute to the market's expansion. With a blend of technological innovation and growing healthcare awareness, the Asia Pacific region is witnessing a surge in demand for cardiovascular devices.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, owing to its robust and mature landscape, encompassing the United States and Canada as key contributors. Known for its advanced medical technologies, this market hosts a wide array of cardiovascular devices, including pacemakers, defibrillators, stents, and imaging tools. Furthermore, factors such as high healthcare spending, sophisticated healthcare infrastructure, and a large patient pool drive market growth. Innovations in minimally invasive procedures, coupled with a strong emphasis on research and development, contribute to the region's leadership in cutting-edge cardiovascular technologies, fostering a competitive market environment with a focus on improving patient outcomes

Key players in the market

Some of the key players in the Cardiovascular Devices Market include Abbott, Cardinal Health, Boston Scientific Corporation, General Electric (GE Healthcare), Medtronic, W. L. Gore & Associates, Inc., Biotronik, Canon Medical Systems Corporation, Siemens Healthcare GmbH., Edwards Lifesciences Corporation, LivaNova PLC, B. Braun Melsungen AG, Johnson & Johnson Services, Inc., Terumo Cardiovascular Systems Corporation, Philips Healthcare, MicroPort Scientific Corporation, Lepu Medical Technology(Beijing)Co Ltd, Occlutech, Getinge AB and AtriCure, Inc.

Key Developments:

In October 2022, Medtronic plc received United States FDA approval for expanded labeling of a cardiac lead that taps into the heart's natural electrical system, giving patients needed therapy while avoiding complications sometimes associated with traditional pacing methods, such as cardiomyopathy.

In October 2022, Biosense Webster, Inc., part of Johnson & Johnson MedTech launched the HELIOSTAR Balloon Ablation Catheter in Europe. The HELIOSTAR Balloon Ablation Catheter is indicated for use in the catheter-based cardiac electrophysiological mapping (stimulating and recording) of the atria and, when used with a compatible multi-channel RF generator, for cardiac ablation.

Device Types Covered:

• Diagnostic and Monitoring Devices
• Therapeutic and Surgical Devices
• Other Device Types

Applications Covered:

• Coronary Artery Disease (CAD)
• Heart Failure
• Cardiac Arrhythmia
• Other Applications

End Users Covered:

• Specialty Clinics
• Hospitals
• Cardiac Centers
• Centers Ambulatory Surgical

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Cardiovascular Devices Market, By Device Type

• 5.1 Introduction
• 5.2 Diagnostic and Monitoring Devices
  • 5.2.1 Remote Cardiac Monitoring
  • 5.2.2 Electrocardiogram (ECG)
• 5.3 Therapeutic and Surgical Devices
  • 5.3.1 Cardiac Assist Devices
  • 5.3.2 Catheters
  • 5.3.3 Cardiac Rhythm Management Devices
  • 5.3.4 Grafts
  • 5.3.5 Stents
  • 5.3.6 Heart Valves
• 5.4 Other Device Types

6 Global Cardiovascular Devices Market, By Application

• 6.1 Introduction
• 6.2 Coronary Artery Disease (CAD)
• 6.3 Heart Failure
• 6.4 Cardiac Arrhythmia
• 6.5 Other Applications

7 Global Cardiovascular Devices Market, By End User

• 7.1 Introduction
• 7.2 Specialty Clinics
• 7.3 Hospitals
• 7.4 Cardiac Centers
• 7.5 Centers Ambulatory Surgical

8 Global Cardiovascular Devices Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest Of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest Of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest Of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest Of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations And Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Abbott
• 10.2 Cardinal Health
• 10.3 Boston Scientific Corporation
• 10.4 General Electric (GE Healthcare)
• 10.5 Medtronic
• 10.6 W. L. Gore & Associates, Inc.
• 10.7 Biotronik
• 10.8 Canon Medical Systems Corporation
• 10.9 Siemens Healthcare Gmbh
• 10.10 Edwards Lifesciences Corporation
• 10.11 Livanova PLC
• 10.12 B. Braun Melsungen AG
• 10.13 Johnson & Johnson Services, Inc.
• 10.14 Terumo Cardiovascular Systems Corporation
• 10.15 Philips Healthcare
• 10.16 Microport Scientific Corporation
• 10.17 Lepu Medical Technology(Beijing)Co Ltd
• 10.18 Occlutech
• 10.19 Getinge AB
• 10.20 Atricure, Inc